Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma

Published:2019-02-25 Issue:5 Volume:94 Page:539-545
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Forsberg Peter A.¹^ORCID,Rossi Adriana C.²,Boyer Angelique²,Tegnestam Linda²,Pearse Roger N.²,Perry Arthur²,Pekle Karen A.²,Jayabalan David²,Ely Scott³,Boussi Leora⁴,Sherbenou Daniel W.¹,Williams Colt¹,Allan John N.²,Coleman Morton²,Niesvizky Ruben²,Mark Tomer M.¹^ORCID

Affiliation:

1. Department of Medicine, Division of HematologyUniversity of Colorado School of Medicine Aurora Colorado

2. Department of Medicine, Division of Hematology/OncologyWeill Medical College of Cornell University, New York Presbyterian Hospital New York New York

3. Department of Pathology, Bristol‐Myers Squibb New York New York

4. New York Medical College Valhalla New York

Funder

Amgen

National Center for Advancing Translational Sciences

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25435

Reference19 articles.

1. International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

2. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

3. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

4. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

5. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy;Current Problems in Cardiology;2023-03

2. Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review;OncoTargets and Therapy;2021-10

3. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma;American Journal of Hematology;2021-09-04

4. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo;Biomacromolecules;2020-04-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3